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Background
Mammalian cells are used extensively in the production
of recombinant proteins, and of monoclonal antibodies
(MAbs) in particular. The trend towards avoiding ani-
mal-derived components in biopharmaceutical produc-
tion processes has led to the extensive use of non-
animal origin hydrolysates such as plant hydrolysates or
yeast hydrolysates. The source of hydrolysates affects
cell growth and productivity and may also affect product
quality. Accordingly, careful consideration should be
given during process and cell culture media develop-
ment, in order to determine the appropriate type and
amount of hydrolysates to be added, for the cell and
product at hand.
In this study, we assessed the impact of several hydro-
lysate additives and chemically defined (CD) commercial
feeds on MAb titers, MAb average specific productivity
(average Qp), cell viabilities and metabolite profiles in
suspension cultures of recombinant CHO cells expres-
sing a monoclonal antibody in shake flasks and 2 L
bioreactors.
Materials and methods
Initial experiments were performed using chemically
defined culture medium in 125 mL shake flasks with 50
mL working volume. CHO cells were seeded at 0.3x10
6
viable cells/mL and incubated at 140 rpm, 36.5°C and
5% CO2. 2L stirred tank bioreactors (Sartorius) were
carried out for 14 days in a fed-batch mode in a chemi-
cally defined medium supplemented with chemically
defined feeds and hydrolysates. Glucose was maintained
between 1 and 6 g/L. At the day of harvest the clarifica-
tion was performed by depth filtration. Analysis of daily
samples included determinations of cell viability, cell
density, metabolites, osmolality and product titer. Pro-
duct concentration of the supernatant samples was
quantified using Octet QK and Protein A high perfor-
mance liquid chromatography (HPLC). Protein charac-
terization of Protein-A purified samples were profiled by
reduced and non reduced SDS PAGE. Isoelectric focus-
ing (IEF) analysis of Protein-A purified MAb was carried
out using a iCE280 IEF Analyzer. Aggregates and mono-
mers proportion were determined by using size exclu-
sion chromatography. Acidic and basic species were
characterized using anion exchange (AEX) HPLC. Oligo-
saccharides were cleaved enzymatically using N-Glyca-
nase, then labeled with 2-aminobenzamide and analyzed
by HPLC using an amide column and a fluorescent
detector.
Results
Several chemically defined feeds and hydrolysates were
assessed on CHO cells expressing a monoclonal anti-
body in fed-batch mode. The performance of the devel-
oped process was compared to an existing in-house
platform process.
Nine different chemically defined feeds were assessed
and added at different concentrations (Table 1). Among
the feeds tested, addition of CD Feed 8 and 9 brought a
150 % improvement on MAb titer on the day of harvest
compared to the platform process. All the MAb titers
measured were ranging from 2 g/L to 6 g/L (Figure 1).
Six different hydrolysates were assessed at different
concentrations in fed-batch mode (Table 1). Among the
feeds tested, addition of hydrolysate 1 and hydrolysate 2
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Supplier Commercial feed name Feed name in the poster
ThermoFischer Cell Boost 1 CD Feed 1
ThermoFisher Cell Boost 2 CD Feed 2
ThermoFisher Cell Boost 3 CD feed 3
ThermoFischer Cell Boost 4 CD Feed 4
ThermoFischer Cell Boost 5 CD Feed 5
ThermoFischer Cell Boost 6 CD Feed 6
Life Tech CHO Feed A CD Feed 7
Life Tech CHO Feed B CD Feed 8
Life Tech CHO Feed C CD Feed 9
BD Biosciences Yeast Extract Hydrolysate 1
BD Biosciences Yeastolate Hydrolysate 2
BD Biosciences Select Phytone Hydrolysate 3
BD Biosciences Ultrapep Soy Hydrolysate 4
Sheffield HyPep 1510 Hydrolysate 5
Sheffield HyPep 4605 Hydrolysate 6
BD Biosciences 3 g/L Yeast Extract + 3.25 g/L Yeastolate Hydrolysate combination 1
BD Biosciences 3.5 g/L Yeast Extract + 2.75 g/L Yeastolate Hydrolysate combination 2
BD Biosciences 4 g/L Yeast Extract + 2.25 g/L Yeastolate Hydrolysate combination 3
BD Biosciences 4.5 g/L Yeast Extract + 1.75 g/L Yeastolate Hydrolysate combination 4
BD Biosciences 5 g/L Yeast Extract + 1.25 g/L Yeastolate Hydrolysate combination 5
BD Biosciences 3 g/L Yeast Extract + 5.1 g/L Yeastolate Hydrolysate combination 6
BD Biosciences 3.5 g/L Yeast Extract + 4.6 g/L Yeastolate Hydrolysate combination 7
BD Biosciences 4 g/L Yeast Extract + 4.1 g/L Yeastolate Hydrolysate combination 8
BD Biosciences 4.5 g/L Yeast Extract + 3.6 g/L Yeastolate Hydrolysate combination 9
BD Biosciences 5 g/L Yeast Extract + 3.1 g/L Yeastolate Hydrolysate combination 10
Figure 1 Relative percentage of improvement on MAb titer. Note: Platform process in shake flask was used as the 100% reference for all the
calculations of relative percentage of improvement on Mab titer measured the day of harvest
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on MAb yield.
To identify potential synergies between hydrolysates,
the best hydrolysates from previous experiments were
selected and were tested in combination at different
ratios on CHO cell cultures (Table 1). Antibody concen-
tration at harvest was 290% higher with some of the
hydrolysate combinations.
Based on feed combination optimization results, the
number of bolus feeds and the feed addition timing
were then fine-tuned using the best hydrolysate combi-
nation. Reducing the number of bolus feeds enabled to
reduce ammonia and osmolality while maintaining a
high MAb titer (Figure 1). Moreover, under these condi-
tions, cell viabilities were maintained above 80%
throughout the culture (data not shown).
Based on experimental results obtained in shake flasks,
the best hydrolysate combination (3 feeds and 4 feeds)
and CD feed were assessed on CHO cells cultured in 2
L stirred tank bioreactors. Cell growth and cell metabo-
lism were monitored daily throughout the cultures in
bioreactors. By feeding the cultures with hydrolysates,
addition of 3 or 4 bolus feeds enabled to attain similar
maximum viable cell count. Addition of chemically
defined feed led to a 30% higher maximum viable cell
count. Cell viabilities were maintained at acceptable
values throughout the cultures in the established culture
conditions. Lactate profiles were similar independently
of the feeding regime. Decreasing the number of hydro-
lysate feeds enabled to maintain osmolality and ammo-
nia at acceptable concentrations for CHO cell growth
and product quality. Cell growth performance and meta-
bolism profiles observed in 2 L bioreactors were com-
parable to those observed in shake flasks.
Product titers have been measured throughout the
fed-batch cultures with the Octet QK system. The MAb
titers were in a 2-6 g/L range for all the tested feeding
regimes at the day of harvest. A combination of hydroly-
sates and a chemically defined feed supplementation
showed an improvement of 296% and 245% on MAb
concentration at the day of harvest in comparison to the
platform process (Figure 1). MAb average specific pro-
ductivity (Qp) was increased by 700% and 360% by add-
ing 4 feeds of hydrolysates and chemically defined feed
respectively. Decreasing the number of hydrolysate feeds
showed a slight decrease on MAb titer and on Qp.
Product quality attributes were determined on cell
culture clarified fluids after Protein-A purification.
Reduced and non reduced SDS electrophoresis, isoelec-
tric focusing (IEF) analysis, gel permeation HPLC, size
exclusion (SEC) chromatography, anion exchange HPLC
(AEX) have been used to characterize the Protein-A
purified MAb. Product quality data was comparable for
all the feeding regimes tested in 2 L bioreactors.
Conclusions
Hydrolysate combination additions significantly
improved MAb production in comparison to single
hydrolysate addition or chemically defined feeds. Num-
ber of bolus feeds and feeding timing optimization
enabled us to improve the process robustness taking
into account the impact of feeding strategy on cell
metabolism and product quality. The feeding regimes
established in shake flasks led to similar culture perfor-
mance in 2 L bioreactors.
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